High Brain Iron Hastens Alzheimer's Disease
By HospiMedica International staff writers Posted on 14 Jun 2015 |
High ferritin levels in the cerebrospinal fluid (CSF) could increase the risk of developing Alzheimer's disease (AD) and accelerate the cognitive decline that comes with it, according to a new study.
Researchers at the University of Melbourne (Australia), Cornell University (Ithaca, NY, USA), and other partners of the Alzheimer’s Disease Neuroimaging Initiative (ADNI; La Jolla, CA, USA) conducted a study to examine the possible link between brain iron levels and cognitive decline in three groups over seven years. Participants included 91 people with normal cognition, 144 people with mild cognitive impairment, and 67 people with diagnosed AD.
The researchers first determined participants’ brain iron levels by measuring the amount of ferritin in the CSF, which surrounds the brain. They continued to perform regular tests and magnetic resonance imaging (MRI) scans to track cognitive decline and changes in the brain over the study period. The results showed that people with higher levels of ferritin (in all groups) suffered faster declines in cognitive abilities, and accelerated shrinking of the hippocampus. Levels of ferritin were also a linked to a greater likelihood of people with mild cognitive impairment developing AD.
The researchers also found that higher levels of ferritin corresponded to earlier ages for diagnoses of AD, roughly three months for every 1 nanogram per milliliter increase. Another finding was that the ferritin was strongly associated with CSF apolipoprotein E (APOE-e4) levels, and that those participants with the AD risk allele, APOE-ɛ4, a gene variant which is known to be the strongest genetic risk factor for the disease, had the highest levels of iron in their brains. The study was published on May 19, 2015, in Nature Communications.
“We think that iron is contributing to the disease progression of Alzheimer's disease; this is strong evidence to base a clinical trial on lowering iron content in the brain to see if that would impart a cognitive benefit,” said lead author neuroscientist Scott Ayton, PhD, of the University of Melbourne. “Lowering CSF ferritin, as might be expected from a drug like deferiprone, could conceivably delay mild cognitive impairment conversion to Alzheimer's disease by as much as three years. Perhaps it's time to refocus the field on looking at iron as a target.”
AD, named after Dr. Alois Alzheimer, who first described it, is a physical disease that is the result of protein buildup in the brain, forming structures called plaques and tangles. These lead to the loss of connections between nerve cells, and eventually to their death and loss of brain tissue. As AD progresses, memory loss, communication, reasoning, and orientation become increasingly severe, and sufferers need more and more day-to-day support from those who care for them. AD affects almost 50% of those over the age of 85, and is the sixth leading cause of death in the US.
Related Links:
University of Melbourne
Cornell University
Researchers at the University of Melbourne (Australia), Cornell University (Ithaca, NY, USA), and other partners of the Alzheimer’s Disease Neuroimaging Initiative (ADNI; La Jolla, CA, USA) conducted a study to examine the possible link between brain iron levels and cognitive decline in three groups over seven years. Participants included 91 people with normal cognition, 144 people with mild cognitive impairment, and 67 people with diagnosed AD.
The researchers first determined participants’ brain iron levels by measuring the amount of ferritin in the CSF, which surrounds the brain. They continued to perform regular tests and magnetic resonance imaging (MRI) scans to track cognitive decline and changes in the brain over the study period. The results showed that people with higher levels of ferritin (in all groups) suffered faster declines in cognitive abilities, and accelerated shrinking of the hippocampus. Levels of ferritin were also a linked to a greater likelihood of people with mild cognitive impairment developing AD.
The researchers also found that higher levels of ferritin corresponded to earlier ages for diagnoses of AD, roughly three months for every 1 nanogram per milliliter increase. Another finding was that the ferritin was strongly associated with CSF apolipoprotein E (APOE-e4) levels, and that those participants with the AD risk allele, APOE-ɛ4, a gene variant which is known to be the strongest genetic risk factor for the disease, had the highest levels of iron in their brains. The study was published on May 19, 2015, in Nature Communications.
“We think that iron is contributing to the disease progression of Alzheimer's disease; this is strong evidence to base a clinical trial on lowering iron content in the brain to see if that would impart a cognitive benefit,” said lead author neuroscientist Scott Ayton, PhD, of the University of Melbourne. “Lowering CSF ferritin, as might be expected from a drug like deferiprone, could conceivably delay mild cognitive impairment conversion to Alzheimer's disease by as much as three years. Perhaps it's time to refocus the field on looking at iron as a target.”
AD, named after Dr. Alois Alzheimer, who first described it, is a physical disease that is the result of protein buildup in the brain, forming structures called plaques and tangles. These lead to the loss of connections between nerve cells, and eventually to their death and loss of brain tissue. As AD progresses, memory loss, communication, reasoning, and orientation become increasingly severe, and sufferers need more and more day-to-day support from those who care for them. AD affects almost 50% of those over the age of 85, and is the sixth leading cause of death in the US.
Related Links:
University of Melbourne
Cornell University
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure